• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 26, 2011

View Archived Issues

Elan, Proteostasis Join Forces in Early Stage Collaboration

Elan Corp. has committed as much as $50 million in a new approach to neurodegenerative disease being pioneered by Cambridge, Mass.-based Proteostasis Therapeutics Inc. The alliance will make use of Proteostasis assets and expertise in protein folding to identify and advance molecular entities that prevent misfolding of protein. Read More

Genentech Scientists Report Antibody Delivery into Brain

In back-to-back papers, scientists from Genentech Inc. reported two potential advances in the fight against Alzheimer's disease: They have managed to make an antibody that inhibits beta-secretase and to deliver that antibody into the brain to lower amyloid beta. Read More

Prometheus the Latest Buy for Nestle's Health Sciences Unit

San Diego-based Prometheus Laboratories Inc., a specialty pharma and diagnostics company that has spent nearly four years in the initial public offering (IPO) queue, will become the latest acquisition of Nestle Health Sciences SA, as the Swiss firm expands its efforts in the new area of science-based nutrition. Read More

Are More Financial Disclosure Requirements in the Works?

WASHINGTON – Citing as their prime evidence Sanofi's strategy to prevent approval of Lovenox biosimilars, two senators are building a case for more disclosure of biopharma's financial ties with nonprofit medical groups, especially when those nonprofits intervene on drug approvals and safety issues. Read More

'G'day' for Pathway: $7.5M for PWT33597 Cancer Phase I

Pathway Therapeutics Inc., a San Francisco-based company built largely on research from New Zealand and funding from Australia, raised $7.5 million from two Australian venture investors and will advance its PWT33597 to a Phase I trial for treatment of patients with advanced solid tumors. Read More

Stock Movers

Read More

Other News To Note

PolyMedix Inc., of Radnor, Pa., reported preclinical data showing its defensin-mimetic antimicrobial compounds are active against oral mucositis, malaria and other pathogens. The data were presented at the American Society of Microbiology annual meeting. Read More

Clinic Roundup

Achillion Pharmaceuticals Inc., of New Haven, Conn., began dosing in a Phase I trial of ACH-2684, a pan-genotypic protease inhibitor in development for chronic hepatitis C virus (HCV) infection. The study is designed to test the safety, tolerability, pharmacokinetic profile and antiviral activity of the drug in three segments: a single ascending dose segment in healthy volunteers, a 14-day multiple ascending doses segment in healthy volunteers and evaluation of three days of oral ascending repeat doses in subjects with either genotype 1 or genotype 2 HCV. Up to 78 healthy volunteers and 40 HCV-infected patients will be enrolled. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe